Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
P R Health Sci J ; 34(2): 83-8, 2015 Jun.
Article in English | MEDLINE | ID: mdl-26061058

ABSTRACT

Vitamin D has been attracting increased attention because of higher prevalences of vitamin D insufficiency and deficiency than expected in areas with sufficient sun exposure. Even though sunlight exposure and diet are the main determinants of vitamin D status, other factors, such as age, race, the use (or not) of sunscreen, medications, and malabsorptive conditions, also affect vitamin D levels. Recent studies have found high prevalences of vitamin D deficiency and insufficiency in different populations. However, there are limited data regarding the prevalence of vitamin D deficiency and insufficiency in Puerto Rico. To shed more light on the subject, we evaluated a sample of 51 internal medicine residents and research fellows, aged from 25 to 39 years at the University District Hospital in San Juan, Puerto Rico, doing so by means of a questionnaire that explored basic socio demographic and lifestyle characteristics and collected anthropometric data; in addition, we obtained blood samples in order to determine 25-hydroxyvitamin D levels. The median 25-hydroxyvitamin D level was 21 ng/mL (range, 7-38 ng/mL). Forty-five participants (88.2%) had 25-hydroxyvitamin D concentrations of lower than 30 ng/mL. We found vitamin D deficiencies in 43.1% of the population and insufficiencies in 45.1%. Contributory factors to our findings include limited exposure to sunlight during periods of high sun intensity, increased body mass index, and a limited area of the body being exposed to sunlight. A relationship between reduced physical activity levels and hypovitaminosis D was also found. Both calcium intake and vitamin D intake, which were markedly below recommended daily allowances, were positively correlated with 25-hydroxy vitamin D levels, but with a weak association.


Subject(s)
Physicians , Vitamin D Deficiency/epidemiology , Adult , Female , Hospitals, District , Hospitals, University , Humans , Male , Prevalence , Puerto Rico
2.
P R Health Sci J ; 32(2): 57-62, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23781620

ABSTRACT

OBJECTIVE: To determine the prevalence of hypothyroidism in an adult female population in Puerto Rico and to determine the relationship between hypothyroidism, bone mineral density and vertebral and non-vertebral fractures in this population. METHODS: Data from the 400 subjects' database of the Latin American Vertebral Osteoporosis Study (LAVOS), Puerto Rico site was reviewed. Patient's medical history, anthropometric data, current medications, laboratories, and DXA results was extracted. Subjects with thyroid dysfunction were identified based on their previous medical history and levels of TSH. Bone Mineral Density was classified using the World Health Organization criteria. Crude prevalence of thyroid dysfunction were estimated with a confidence of 95% and weighted by the population distribution by age, according to the distribution by age group in the 2000 census. Bone mineral densities and prevalence of vertebral and non-vertebral fractures were compared among the groups. RESULTS: The weighted prevalence of hyperthyroidism in this population was 0.0043% (95% CI: -0.0021%, 0.0107%). The weighted prevalence of hypothyroidism was 24.2% (95% CI: 19.9%, 28.4%). Increased prevalence of hypothyroidism was found in participants 70 years or older. The mean BMD at spine, hip and femoral neck was similar among the groups. No difference in the proportion of participants with vertebral and non-vertebral fractures was found among the groups. CONCLUSION: Our study found a high prevalence of hypothyroidism among adult postmenopausal females in Puerto Rico. No association between hypothyroidism and decreased bone mineral densities, vertebral or non-vertebral fractures was found in this population.


Subject(s)
Hypothyroidism/epidemiology , Aged , Aged, 80 and over , Body Mass Index , Bone Density , Comorbidity , Databases, Factual , Female , Femur Neck/chemistry , Femur Neck/pathology , Fractures, Spontaneous/epidemiology , Hip Joint/chemistry , Hip Joint/pathology , Humans , Hypothyroidism/drug therapy , Hypothyroidism/ethnology , Latin America/epidemiology , Lumbar Vertebrae/chemistry , Lumbar Vertebrae/pathology , Middle Aged , Multicenter Studies as Topic/statistics & numerical data , Obesity/epidemiology , Osteoporosis, Postmenopausal/epidemiology , Osteoporosis, Postmenopausal/metabolism , Osteoporosis, Postmenopausal/pathology , Postmenopause/blood , Prevalence , Puerto Rico/epidemiology , Retrospective Studies , Sampling Studies , Spinal Fractures/epidemiology , Thyroid Hormones/blood , Thyroid Hormones/therapeutic use , Thyrotropin/blood
3.
P R Health Sci J ; 29(4): 377-84, 2010 Dec.
Article in English | MEDLINE | ID: mdl-21261177

ABSTRACT

OBJECTIVE: The participation of Puerto Rico in the Latin American Vertebral Osteoporosis Study (LAVOS) has allowed us to study the magnitude of the problem of osteoporosis in the female population residing in San Juan. The objective of LAVOS was to estimate the prevalence of vertebral fractures in Latin American women using a random sample of females selected from cities across five Latin American countries. METHODS: A probability cluster design was employed to select a random sample of households in San Juan, Puerto Rico, in order to interview 400 females aged 50 years and over. A 30-minute face-to-face interview gathered data on demographics, risk factors, and life styles. Data regarding bone mineral densities of the spine and hip by DXA and lateral dorsolumbar X-rays were obtained using international protocols; digital morphometry was used to determine vertebral deformities, with the results being classified according to Eastell criteria. This article summarizes the main findings observed in San Juan, Puerto Rico. RESULTS: Overall weighted prevalence of vertebral fractures was 11.2% (95% CI: 8.5%, 14.7%). Age-specific prevalence of vertebral fractures was as follows: 5.4% (95% CI: 2.7%, 10.7%) in the 50-59 years age group, 8.3% (95% CI: 4.4%, 15.1%) in the 60-69 years group, 16.2% (95% CI: 10.5%, 25.0%) in the 70-79 years group, and 22.4% (95% CI: 13.3%, 35.1%) in participants > or = 80 years. Factors significantly associated with vertebral fractures were being 70-79 years old (adjusted POR70-79 vs. 50-59 = 2.9; 95% CI: 1.1, 7.4), being > or = 80 years old (adjusted POR > or = 80 vs .50-59 = 3.3; 95% CI: 1.2, 9.4), and a T-score < or = -2.5 in the lumbar spine (adjusted POR = 2.5; 95% CI: 1.5, 5.7) and in the femoral neck (adjusted POR = 3.5; 95% CI: 1.5, 8.0). Personal history of fractures was marginally associated with vertebral fractures after adjusting for the remaining risk factors (adjusted POR = 2.0; 95% CI: 1.0, 4.0). Nearly 94% of the women with vertebral fractures were not aware of their bone status. Using the WHO classification, we determined that 71% had osteoporosis, 21%, osteopenia, and 8%, normal bone mineral densities. Bone mineral densities in the lumbar spine and femoral neck were significantly lower in women with vertebral fractures. Non-vertebral fractures were more common in women with a personal history of prior vertebral fractures. The prevalence of the most common non-vertebral fractures were hip, 1% (95% CI: 0.4%, 2.7%), and wrist, 5.9% (95% CI: 4.0%, 8.7%), respectively. CONCLUSION: This is the first population-based study of osteoporotic fractures in Puerto Rico and should serve as a guide to health providers and policy makers in the prevention and treatment of this disease.


Subject(s)
Spinal Fractures/epidemiology , Aged , Aged, 80 and over , Female , Humans , Middle Aged , Prevalence , Puerto Rico/epidemiology
4.
Ethn Dis ; 18(4): 434-41, 2008.
Article in English | MEDLINE | ID: mdl-19157247

ABSTRACT

OBJECTIVE: The metabolic syndrome is associated with a high risk of diabetes and cardiovascular disease, and Hispanics in the United States have higher rates than do other ethnic groups. We assessed the prevalence of the metabolic syndrome and its individual components in Puerto Rican adults. METHODS: We conducted a cross-sectional study that used a probability cluster design to select a sample of households of the San Juan metropolitan area from 2005 through 2007. A total of 859 persons aged 21-79 years completed a face-to-face interview, blood pressure and waist circumference measurements, and blood sampling. Our primary outcome measure was metabolic syndrome as defined by the updated NCEP-ATP criteria. RESULTS: Prevalence of the metabolic syndrome was 43.3%; 45.3% for men and 42.2% for women (P>.05). Prevalence significantly rose with age, from 12.8% among participants aged 21-29 years to 58.2% for participants aged 70-79 years (P<.001). Corresponding increases in the prevalence of the metabolic syndrome in both men and women were also observed; the prevalence peaked in men aged 50-59 years (62.6%) and in women aged 70-79 years (65.2%). Elevated glucose (49.8%) and abdominal obesity (49.0%) were the most common components of the metabolic syndrome, followed by elevated blood pressure (46.1%), reduced high-density lipoprotein cholesterol (46.0%), and elevated triglycerides (31.3%). Substantial variations were found between men and women in the prevalence of individual components. CONCLUSIONS: Puerto Ricans have a high prevalence of the metabolic syndrome. This health disparity has implications for diabetes and cardiovascular prevention programs.


Subject(s)
Metabolic Syndrome/epidemiology , Adult , Aged , Blood Glucose/analysis , Female , Humans , Hyperlipidemias/epidemiology , Hypertension/epidemiology , Life Style , Male , Middle Aged , Obesity/epidemiology , Prevalence , Puerto Rico/epidemiology , Risk Factors , Urban Population , Young Adult
5.
J Bone Miner Res ; 20(7): 1244-53, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15940379

ABSTRACT

UNLABELLED: An 18-month randomized double-blind study was conducted in postmenopausal women with osteoporosis to compare the effects of once-daily teriparatide 20 microg with alendronate 10 mg on bone histomorphometry. Biopsies were obtained from 42 patients. Indices of bone formation were significantly higher after 6 or 18 months of teriparatide compared with alendronate treatment. INTRODUCTION: Alendronate and teriparatide increased BMD, assessed by DXA, by different mechanisms of action, supported by changes in biochemical markers of bone turnover. The purpose of this cross-sectional study was to explore the differential effects of these two osteoporosis treatments at the bone tissue level by examining bone histomorphometric parameters of bone turnover after either 6 or 18 months of treatment. MATERIALS AND METHODS: Patients were a cohort from a randomized parallel double-blind study conducted to compare the effects of once-daily teriparatide 20 microg and alendronate 10 mg in postmenopausal women with osteoporosis. Transiliac crest bone biopsies were obtained after tetracycline double labeling from 42 patients treated for 6 months (n = 23) or 18 months (n = 14); 5 additional patients were biopsied from contralateral sides at 6 and 18 months. Biopsy specimens adequate for quantitative analysis were analyzed by 2D histomorphometry from 17 patients at 6 months (teriparatide, n = 8; alendronate, n = 9) and 15 patients at 18 months (teriparatide, n = 8; alendronate, n = 7). Data were analyzed by two-sample tests. RESULTS: Histomorphometric indices of bone formation were significantly and markedly greater in the teriparatide group than in the alendronate group at 6 and 18 months, whereas indices of bone resorption were only significantly greater in the teriparatide group than in the alendronate group at 6 months. Bone formation and activation frequency were significantly lower at 18 months compared with 6 months in the teriparatide group, returning to levels comparable with untreated postmenopausal women. In the teriparatide group, the peak in histomorphometric bone formation indices coincided with peak levels for N-terminal propeptide of type I collagen, a biochemical marker of bone formation. The degree of mineralization was lower at 18 months than at 6 months with treatment in both groups but was not different between groups. CONCLUSIONS: These results confirm the opposite mechanisms of action of teriparatide and alendronate on bone remodeling and confirm the bone formation effect of teriparatide.


Subject(s)
Alendronate/therapeutic use , Bone Remodeling/drug effects , Osteoporosis, Postmenopausal/drug therapy , Teriparatide/therapeutic use , Absorptiometry, Photon , Aged , Biomarkers/analysis , Bone Density/drug effects , Calcification, Physiologic/drug effects , Female , Humans , Ilium/pathology , Middle Aged , Postmenopause/drug effects , Postmenopause/metabolism
6.
P. R. health sci. j ; 19(4): 329-333, Dec. 2000.
Article in English | LILACS | ID: lil-334085

ABSTRACT

BACKGROUND: Osteopenia has been reported in association to Inflammatory Bowel Disease, and in particular Crohn's disease. The use of corticosteroids, resection of the ileum, malabsorption, poor calcium intake, and the effect of inflammatory cytokines have all been considered as contributing factors. As Crohn's disease is more prevalent in young people, when peak bone mass is achieved, the presence of osteopenia is especially significant. OBJECTIVES: The aim of this study was to evaluate the bone density of patients with Crohn's disease in the University of Puerto Rico IBD Clinic; to determine the prevalence of osteopenia in these patients and to correlate bone mineral density with risk factors for osteopenia. METHODS: Sixty-six patients, 30 males and 36 females were included. After informed consent, demographic, clinical and metabolic data was obtained. Serum albumin, calcium, inorganic phosphorus and alkaline phosphatase were measured. Body mass index (BMI) was calculated. Bone density was determined by DEXA of the lumbar spine and femur and expressed as the Z score (standard deviations from normal correlated with sex and age). Severe osteopenia was a Z score > or = -2 and osteopenia was Z < or = -1.99 or > or = 1.01. Results were expressed in means. Pearson correlation coefficient was used for quantitative variables and Pearson chi-square for categorical values. RESULTS: Osteopenia was present in the hip in 69 and in the lumbar spine in 68. Most patients had received steroids; the difference between treated and not treated patients was not significant. Osteopenia did not correlate with ileal resection, gender, BMI, disease characteristics or biochemical parameters. CONCLUSIONS: Low bone density was frequent in patients with Crohn's disease, but no specific risk factors could be identified. Bone density should be determined in patients with Crohn's disease in order to institute appropriate therapeutic measures.


Subject(s)
Humans , Male , Female , Adult , Bone Diseases, Metabolic , Crohn Disease/complications , Bone Density , Bone Diseases, Metabolic , Prevalence , Puerto Rico , Risk Factors
7.
P. R. health sci. j ; 17(4): 309-16, Dec. 1998. tab, graf
Article in English | LILACS | ID: lil-234843

ABSTRACT

From 1960 to 1990, one hundred twenty eight (128) subjects with primary hyperparathyroidism were operated in the University Hospital. The medical records were reviewed. Serum and urine chemistries were done by conventional methods, serum PTH was done by RIA's (N-, C-, and midregion) and intact by IRMA and 1,25 dihydroxycholecalciferol by a non equilibrium receptor assay from calf thymus and preceded by double Sep-Pak chromatography. The distal third of the radius (nondominant arm) was used to evaluate radial bone density (RBD), using single photon absorptiometry (Norland) and the lumbar bone density (LBD) was measured by dual energy X Ray absorptiometry (DEXA). The RBD was done in 41 females and 15 males and the LBD in 12 females and 4 males. The series comprised 95 females, age range from 15 to 79 years, and 33 males, age range from 14 to 69 years. Prominent clinical features included nephrolithiasis in 72 subjects (56 per cent), osteitis fibrosa cystica in 2, isolated familial hyperparathyroidism in 4 subjects in one family, 7 subjects with MEN-1 in 3 families, and 4 subjects with MEN-2 in one family. Only 7 subjects were asymptomatic. Serum calcium was elevated in all, serum alkaline phosphatase was elevated in 24 per cent and urinary hydroxiproline was increased in 48 per cent. Serum phosphorus was low in 92 per cent. PTH assay was either elevated or inappropriately normal for the serum calcium in all patients tested. Serum 1,25 D was elevated in 57 per cent. The PTH level was positively correlated with the serum calcium (r = 0.70), but had no significant correlation with the serum phosphorus and the 1,25 D. The RBD expressed as the standard deviation from that of the mean for age and sex matched controls was > or = 2 SD below the mean in 39 per cent of females and in 40 per cent of males. In contrast to the RBD none of the subjects tested had a LBD > or = 2 SD below the age and sex adjusted mean. 103 subjects had adenomas, 20 primary hyperplasia, 2 carcinomas and in 3 surgical exploration was unsuccessful. As to the outcome of Surgery, 117 (93 per cent) were cured. Thus, in this series, successful surgery for primary hyperparathyroidism is the rule. Primary hyperparathroidism is rarely asymptomatic and appendicular bone disease and nephrolithiasis are commonly seen.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Adenoma/diagnosis , Bone Density , Calcitriol/blood , Calcium/blood , Hyperparathyroidism/diagnosis , Parathyroid Neoplasms/diagnosis , Adenoma/metabolism , Adenoma/surgery , Alkaline Phosphatase/blood , Diagnosis, Differential , Phosphorus/blood , Hydroxyproline/urine , Hyperparathyroidism/metabolism , Hyperparathyroidism/surgery , Linear Models , Parathyroid Hormone/blood , Parathyroid Neoplasms/metabolism , Parathyroid Neoplasms/surgery , Treatment Outcome
8.
P. R. health sci. j ; 16(3): 241-4, sept. 1997. tab
Article in English | LILACS | ID: lil-212525

ABSTRACT

The World Health Organization criteria for the diagnosis of Osteopenia and Osteopoposis was applied to a control group of 33 females ages 50 to 59 years and 24 females ages 60 to 69 years. The general exclusion criteria for the selection of subjects included early menopause and diseases, use of drugs and toxic habits such as smoking and alcoholism, known to affect bone and mineral metabolism. Bone mineral densities were measured with a DEXA Hologic, model 1000. In the reference population mean peak bone mineral density expressed in g/cm2 was 1.051 (SD = 0.119) for the lumbar spine at age 30 to 39 years and for the femoral neck 0.861 (SD = 0.098) at age 20 to 29 years. Bone densities below 1 to 2.5 SD from mean peak bone mass ranged from 0.932 to 0.754 g/cm2 in the lumbar spine and 0.763 to 0.616 g/cm2 for the femoral neck. The mean age of the pooled group was 58.4 years. The prevalence of osteopenia in the pooled group was 42 per cent for the lumbar spine and 56 per cent for the femoral neck and of osteoporosis, 12 per cent for the lumbar spine and 8.7 per cent for the femoral neck. A similar prevalence has been found by other investigators in hispanic populations. Such a high percentage of females with osteopenia implicates that bone densitometry must be done in the perimenopausal years and in young individuals at risk so as to proceed with early medical intervention to prevent osteoporosis.


Subject(s)
Humans , Female , Middle Aged , Bone Diseases, Metabolic , Osteoporosis , Prevalence , Puerto Rico
9.
Bol. Asoc. Méd. P. R ; 82(10): 450-3, oct. 1990. tab
Article in English | LILACS | ID: lil-96080

ABSTRACT

Several reports have appeared in the literature suggesting that Vitamin D metabolites and analogues may be useful for the treatment of psoriasis. This is a report of an open study in which the efficacy of 1, Alpha-25-dihydroxyvitamin D (Calcitriol) is evaluated in cases of moderate to severe psoriasis. Study of ten cases showed moderate improvement in four when using calcitriol at a daily dose of 0.5 ug for a period of three months. All Vitamin D metabolites were within normal limits during and after the trial. Further trials with calcitriol as an adjuvant therapy to topical steroids or photochemotherapy, as well as the development of topical Vitamin D analogues may be the future of this novel therapeutic alternative for psoriasis


Subject(s)
Humans , Adult , Middle Aged , Male , Female , Calcitriol/therapeutic use , Psoriasis/drug therapy , Calcitriol/adverse effects , Clinical Trials as Topic
10.
P. R. health sci. j ; 4(1): 47-56, Mar. 1985. tab
Article in English | LILACS | ID: lil-27913

ABSTRACT

El metabolismo de vitamin D3 rotulada con titrio (D3-3H) fue estudiado en un grupo pequeño de sujetos controles y sujetos con esprú tropical, al cual les fue administrado de 8 a 10 microcuries del isotopo por vía oral o intravenosa. La media vida del isotopo (D3-3H) fue hallada normal en 2 controles, baja en un sujeto con esprú tropical que presentaba esteatorrea y disminuída en un sujeto con esprú tropical sin esteatorrea. Cuando la dosis fue administrada por vía oral la media vida de D3-3H fue de 35 horas en el control, y no se detectó ninguna radioactividad en el plasma del sujeto con esprú tropical y esteatorrea. A las 24 horas de haber recibido la dosis por vía intravenosa el porciento de radioactividad en el plasma como HCC-3H fue dos veces mayor en los sujetos con esprú tropical que en los controles. La absorción oral del D3-3H fue de 50,5% en el sujeto con esprú tropical y esteatorrea y 86,8% en el sujeto con esprú tropical parcialmente tratado. Estos resultados demostraron una depuración rápida del D3-3H en el sujeto con esprú tropical y esteatorrea indicando depleción de las reservas de vitamina D3 en los tejidos y una disminución de la absorción oral del D3-3H. La presencia de un porciento de la radioactividad en el plasma como HCC-3H dos veces mayor en los sujetos con esprú tropical que en los controles, al administrarse la dósis por vía intravenosa y oral indica que no existe ninguna alteración en el metabolismo de vitamina D3 en esprú tropical


Subject(s)
Middle Aged , Humans , Male , Female , Cholecalciferol/metabolism , Sprue, Tropical/metabolism , Administration, Oral , Cholecalciferol/administration & dosage , Injections, Intravenous , Isotope Labeling , Kinetics , Tritium
SELECTION OF CITATIONS
SEARCH DETAIL
...